Evidence method
Level · gp.fundamentals.capex_revenue_ratio
325.94% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
IMDX · Jun 30, 2026
Insight Molecular Diagnostics Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001642380-26-000011General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-3877.82% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-53.86% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
86.61% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
65.69% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-4770.71% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
1876.99% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
276.57% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History15 statesHistory building
Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/5 normalizedLevel 3Jun 30, 20230/5 normalizedLevel 3Sep 30, 20230/5 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20245/8 normalizedLevel 3Mar 31, 20255/8 normalizedLevel 3Jun 30, 20255/8 normalizedLevel 3Sep 30, 20256/8 normalizedLevel 3Dec 31, 20257/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20267/8 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 1915.63%
- Current
- 325.94%
- Delta
- -1589.68%
- Previous
- -23871.88%
- Current
- -3877.82%
- Delta
- 19994.05%
- Previous
- -98.50%
- Current
- -53.86%
- Delta
- 44.64%
- Previous
- 1193.75%
- Current
- 86.61%
- Delta
- -1107.14%
- Previous
- 46.88%
- Current
- 65.69%
- Delta
- 18.82%
- Previous
- -13790.63%
- Current
- -4770.71%
- Delta
- 9019.91%
- Previous
- 15478.13%
- Current
- 1876.99%
- Delta
- -13601.14%
- Previous
- 1921.88%
- Current
- 276.57%
- Delta
- -1645.31%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · In Vitro & In Vivo Diagnostic Substances peers →Has State · Insight Molecular Diagnostics Inc. →Transitioned To · IMDX Fundamental State →Transitioned To · IMDX CAPEX_INTENSITY_DECREASED →Transitioned To · IMDX CASH_GENERATION_INCREASED →Transitioned To · IMDX GROWTH_INCREASED →Transitioned To · IMDX INVENTORY_PRESSURE_DECREASED →Transitioned To · IMDX MARGIN_INCREASED →Transitioned To · IMDX PROFITABILITY_INCREASED →Transitioned To · IMDX R_AND_D_INTENSITY_DECREASED →Transitioned To · IMDX SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.